IFS, the global enterprise applications company, has been selected to provide enterprise resource planning (ERP) software to The Butantan Institute, a Brazilian biomedical research centre affiliated to the São Paulo State Secretary of Health. The agreement includes licenses and services valued in excess of US$2 million.

The Butantan Institute is one of the largest biomedical research centres in the world, and produces 90% of the vaccines and serums used in Brazil for preventive and curative use. The Butantan Institute also conducts public health-related studies and research, and conducts scientific missions in Brazil and abroad through major non-governmental organisations like the World Health Organisation, UNICEF and the United Nations.

“IFS is a proven and safe choice in major enterprise software selection processes in Latin America,” LatinIFS CEO Lávio Falcão said. “We have built-in support for Brazilian tax code including Nota Fiscal Documents, and a strong service and support presence in the region. Particularly in industries that are heavily regulated, requiring serialisation and documented quality processes, we plan to remain a significant force in Latin America.”

Process manufacturing is one of IFS’ targeted markets. IFS provide industry-specific functionality for enterprises in chemicals, food & beverage, paint & ink, and pharmaceuticals. IFS Applications supports all critical business processes, including material compliance, batch balancing, recipe management, quality management and demand planning. The application suite also includes solutions for enterprise asset management, product lifecycle management, customer relationship management, finance and human resource management.

IFS process manufacturing customers include Jotun, Dyrup, Willamette Valley Company, AkzoNobel, Sherwin-Williams, Farrow & Ball, Teknos, Imerys, Becker Industrial Coatings, ACO Hud, LGC Ltd, Neste Oil, Oriflame, Heaven Hill Distilleries Inc, Bridor, Cloetta, Boyd’s Coffe, Tazo Tea, W.Grants, Bolix S.a., Diamond Pet Foods, Kettle Foods, Bronco Wine and Chingford Fruit.

Editorial contacts
Mark Boulton
44 1494 428900
press@ifsworld.com

Frédéric Guigues
Telefon: 46 8 58 78 45 00
frederic.guigues@ifsworld.com

About

After an 1899 outbreak of bubonic plague in the port of Santos in 1899, the government to acquire the Butantan Farm and installed a laboratory for the production of anti-plague serum. This laboratory was recognized as an autonomous institution in February 1901. Today, The Institute conducts biomedical research in many areas, including molecular biology, immunology and epidemiology. Besides its research laboratories, production units and specialized library, it operates an animal breeding center used to generate antidotes for various bites and stings, and accepts donations of serpents, arthropods and other animals. The Butantan Institute is one of the major tourist and educational attractions in a vast park area in the of Butantã neighborhood in São Paulo. It has a serpentarium, a historical museum, a biological museum, and a museum of microbiology. The venom farm is a major attraction, and visitors can see the snakes housed in representations of their natural environments. The park also contains a number of rare species of tree. More information on The Butantan Institute is available at www.butantan.gov.br.

IFS
IFS is a public company (XSTO: IFS) founded in 1983 that develops, supplies, and implements IFS Applications™, a component-based extended ERP suite. IFS focuses on industries where management of any of the following four core processes is strategic: service & asset, manufacturing, supply chain, and projects. The company has 2,100 customers and is present in approximately 60 countries with 2,800 employees in total. Net revenue in 2012 was SKr 2.7 billion. More information on IFS is available at www.IFSWORLD.com
Follow us on Twitter: @ifsworld
Visit the IFS Blogs on technology, innovation and creativity: http://blogs.ifsworld.com/
IFS discloses the information herein pursuant to the Financial Instruments Act (1991:980) and/or the Securities Markets Act (2007:528). The information was submitted for publication on August 1, 2013, at 5:00 p.m. CEST.